臨床婦人科産科76巻3号

2022年04月発行

今月の臨床 がん遺伝子検査に基づく婦人科がん治療―最前線のレジメン選択法を理解する 治療薬

PARP阻害薬の使い分け（初回・再発）

著者： 武隈宗孝¹

所属機関： ¹静岡県立静岡がんセンター婦人科

ページ範囲：P.361 - P.367

●適格性のある患者に対し，確実にPARP阻害薬を処方する．

●プラチナ感受性再発症例に対するPARP阻害薬は，服用方法や副作用，さらに合併症などを含めたそれぞれの患者のバックグラウンドを鑑みて処方を個別に検討する．

●初回治療におけるPARP阻害薬は，バイオマーカーの結果に惑わされず，最初に「初回化学療法レジメン＝TC療法かddTC療法か，TC＋ベバシズマブか」を個別で検討する．

参考文献

1）Ledermann J, et al : Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cance. N Engl J Med 366 : 1352-1392, 2012

2）Ledermann J, et al : Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer : a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15 : 852-861, 2014

3）Coleman RL, et al : Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer（NRG Oncology/Gynecologic Oncology Group study GOG-0213）: a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18 : 779-791, 2017

4）Aghajanian C, et al : OCEANS : a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30 : 2039-2045, 2012

5）Pujade-Lauraine E, et al : Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation（SOLO2/ENGOT-Ov21）: a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18 : 1274-1284, 2017

6）Mirza MR, et al : Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375 : 2154-2164, 2016

7）Wu XH, et al : Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose（NORA）: a randomized double-blind, placebo-controlled phase III trial. Ann Oncol 32 : 512-521, 2021

8）Moore K, et al : Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379 : 2495-2505, 2018

9）González-Martín A, et al : Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381 : 2391-2402, 2019

10）Ray-Coquard I, et al : Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381 : 2416-2428, 2019

11）Coleman RL, et al : Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 381 : 2403-2415, 2019